Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy

Abe,Akiko; Furumoto,Hiroyuki; Nishimura,Masato; Irahara,Minoru; Ikushima,Hitoshi

doi:10.3892/ol.2011.516

Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy

Authors:
- Akiko Abe
- Hiroyuki Furumoto
- Masato Nishimura
- Minoru Irahara
- Hitoshi Ikushima
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan, Department of Radiology, Tokushima University School of Medicine, Tokushima 770-8503, Japan
Published online on: December 6, 2011 https://doi.org/10.3892/ol.2011.516
Pages: 571-576

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to retrospectively evaluate the efficacy and toxicities of adjuvant chemotherapy with paclitaxel and carboplatin (TC) following concurrent cisplatin-based chemoradiation (CCRT) in patients with cervical cancer with lymphadenopathy (N1). A total of 37 patients with FIGO stage IB2-IVA cervical carcinoma with N1 (median age 57 years, range 31-74 years) were enrolled. External beam radiation therapy was followed by high-dose-rate brachytherapy. In cases of suspected para-aortic lymphadenopathy or common iliac lymph node involvement, extended radiotherapy fields were applied. Positive lymph nodes were externally radiated. Cisplatin was administered weekly at a dose of 30 mg/m2 during external beam radiation therapy. Adjuvant therapy was administered to 17 patients and comprised carboplatin (6 mg/ml/min) and paclitaxel (175 mg/m2) administered monthly after CCRT, and repeated every 4 weeks for 3‑6 cycles. Over a median 21.5‑month follow‑up, no significant differences were found in the recurrence rate, progression-free survival, overall survival, or median interval to recurrence with N1 cervical cancer patients between the two groups. Patients with para-aortic lymphadenopathy who received CCRT and adjuvant chemotherapy had a more favorable overall and disease‑free survival than those treated with CCRT alone. However, 16/17 patients developed grade 3-4 leukopenia and 14/17 patients developed severe hematologic toxicity during adjuvant chemotherapy. In conclusion, adjuvant chemotherapy consisting of full dose TC therapy after CCRT was not well tolerated in general and exhibited no benefit to N1 cervical cancer patients. However, it may be of therapeutic advantage over CCRT alone in cervical cancer patients with para-aortic lymphadenopathy.

View Figures

View References

1	Center for Cancer Control and Information Services, National Cancer Center, Japan, 2010 (ganjoho.jp).
2	Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
3	Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
4	Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL and Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para–aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 17:1339–1348. 1999.PubMed/NCBI
5	Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
6	Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 22:872–880. 2004. View Article : Google Scholar
7	Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Colingwood M and Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
8	Kim YB, Cho JH, Keum KC, Lee CG, Seong J, Suh CO and Kim GE: Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecol Oncol. 104:58–63. 2007. View Article : Google Scholar : PubMed/NCBI
9	Choi CH, Lee JW, Kim WY, Nam HR, Kim BG, Hum SJ, Lee JH and Bae DS: Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results. Int J Rad Oncol Biol Phys. 68:817–822. 2007. View Article : Google Scholar : PubMed/NCBI
10	Japan Society of Gynecologic Oncology. Cervical cancer treatment guidelines. 2007
11	Ikushima H, Osaki K, Furutani S, Yamashita K, Kawanaka T, Kishida Y, Wamoto S, Takegawa Y, Kudoh T and Nishitani H: Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Rad Med. 24:115–121. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sakuragi N: Up-to-date management of lymph node metastasis and the role of tailred lymphadenenctomy in cervical cancer. Int J Clin Oncol. 12:165–175. 2007. View Article : Google Scholar : PubMed/NCBI
13	Berman ML, Keys H, Creasman W, Reasman W, DiSaia P, Bundy B and Blessing J: Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes. Gynecol Oncol. 19:8–16. 1984. View Article : Google Scholar : PubMed/NCBI
14	Benedetti PP, Basile S and Angioli R: Pelvic and aortic lymphadenectomy in cervical cancer: the standardization of surgical procedure and its clinical impact. Gynecol Oncol. 113:284–290. 2009. View Article : Google Scholar : PubMed/NCBI
15	Vidaurreta J, Bermudez A, Di Paola G and Sardi J: Laparoscopic staging in locally advanced cervical carcinoma: a new possible philosophy? Gynecol Oncol. 75:366–371. 1999. View Article : Google Scholar : PubMed/NCBI
16	Grigsby PW, Dehdashi F and Siegel BA: FDG-PET evaluation of carcinoma of the cervix. Clin Pos Image. 2:105–109. 1999. View Article : Google Scholar : PubMed/NCBI
17	Rose PG and Bundy BN: Chemoradiation for locally advanced cervical cancer: does it help? J Clin Oncol. 20:891–893. 2002.PubMed/NCBI
18	Grigsby PW, Perez CA, Chao KS, Herog T, Mutch DG and Rader J: Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Rad Oncol Biol Phys. 49:733–738. 2001. View Article : Google Scholar : PubMed/NCBI
19	Walker JL, Morrison A, DiSilvestro P and von Gruenige VE: A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes. Gynecol Oncol. 112:78–84. 2009. View Article : Google Scholar
20	Zhang MQ, Liu SP and Wang XE: Concurrent chemotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of phase II study. Int Rad Oncol Biol Phys. 78:821–827. 2010. View Article : Google Scholar
21	Rose PG, Lessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 17:2676–2680. 1999.
22	Sit AS, Kelley JL, Gallion HH, Kunschner AJ and Edwards RP: Paclitaxel and carboplatin for recurrence or persistent cancer of the cervix. Cancer Invest. 22:368–373. 2004. View Article : Google Scholar : PubMed/NCBI